Abstract
A few years ago it was reported that some growth-hormone-deficient children had developed leukemia following therapy with human growth hormone. This raised concern that this therapy may stimulate tumor development. Since it is known that the tendency to develop cancer is closely related to chromosome breakage, we decided to investigate whether recombinant human growth hormone (rhGH) therapy can increase chromosome fragility. Ten short normal children were studied during their first year of treatment. Lymphocytes were collected at 0, 6 and 12 months of rhGH therapy, and we assessed the rate of spontaneous chromosome aberrations, the frequency of sister chromatid exchanges, the proliferative rate indices, the expression of common fragile sites induced by aphidicolin, and the sensitivity towards the radiomimetic action of bleomycin. At 6 months of therapy, there was a significant increase in bleomycin-induced chromosome aberrations, which remained unchanged after 1 year of treatment. An increase in spontaneous chromosome rearrangements at 6 and 12 months of therapy was also observed. These findings are further supported by data obtained from the analysis of 16 short normal children already on rhGH therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bender MA, Preston RJ, Leonard RC, Pyatt BE, Gooch PC, Shelby MD (1988) Chromosomal aberration and sister-chromatid exchange frequencies in peripheral blood lymphocytes of a large population sample. Mutat Res 204:421–433
Braekeleer M de (1987) Fragile sites and chromosomal structural rearrangements in human leukemia and cancer. Anticancer Res 7:417–422
Ezzat S, Melmed S (1991) Are patients with acromegaly at increased risk for neoplasia? J Clin Endocrinol Metab 72:245–249
Fisher DA, Job JC, Preece MA, Underwood LE (1988) Leukemia in patients treated with growth hormone. Lancet 1:1159–1160
Furuya T, Ochi H, Watanabe S (1989) Common fragile sites in chromosomes of bone marrow cells and peripheral blood lymphocytes from healthy persons and leukemia patients. Cancer Genet Cytogenet 43:131–138
Furuya T, Hagiwara J, Ochi H, Tokuhiro H, Kikawada R, Karube T, Watanabe S (1991) Changes of common fragile sites on chromosome according to the menstrual cycle. Hum Genet 86:471–474
Gebhart E (1981) Sister chromatid exchanges (SCE) and structural chromosome aberration in mutagenicity testing. Hum Genet 58:235–254
German J (1983) Patterns of neoplasia associated with the chromosome breakage syndrome. In: Chromosome mutations and neoplasia. Liss, New York, pp 97–134
Greulich WW, Pyle SI (1959) Radiographic atlas of skeletal development of the hand and wrist. 2nd edn. Stanford University Press, Stanford, Calif
Hsu TC, Cherry LM, Samaan NA (1985) Differential mutagen susceptibility in cultured lymphocytes of normal individuals and cancer patients. Cancer Genet Cytogenet 17:307–313
Miller O (1987) Structure and organization of mammalian chromosomes: normal and abnormal. In: McKusick VA, Roderick TH, Mori J, Paul NW (eds) Medical and experimental mammalian genetics: a perspective. Liss, New York, pp 19–63
Perry P, Wolff S (1974) New Giemsa method for the differential staining of sister chromatids. Nature 251:156–158
Povirk LF, Finley Austin MJ (1991) Genotoxicity of bleomycin. Mutat Res 257:127–143
Preston RJ, San Sebastian JR, McFee AF (1987) The in vitro human lymphocyte assay for assessing the clastogenicity of chemical agents. Mutat Res 189:175–183
Shafik HM, Au WW, Legator MS (1988) Chromosomal radiosensitivity of Down syndrome lymphocytes at different stages of the cell cycle. Hum Genet 78:71–75
Spadari S, Sala F, Pedrali-Noy G (1982) Aphidicolin: a specific inhibitor of nuclear DNA replication in eucaryotes. Trends Biochem Sci 7:29–32
Spadoni GL, Spagnoli A, Cianfarani S, Del Principe D, Menichelli A, Di Giulio S, Boscherini B (1991) Enhancement by growth hormone of phorbol diester-stimulated respiratory burst in human polymorphonuclear leukocytes. Acta Endocrinol 124:589–594
Stahnke N, Zeisel HJ (1989) Growth hormone therapy and leukemia. Eur J Pediatr 148:591–596
Sutherland GR, Ledbetter DH (1989) Report of the committee on cytogenetic markers. Cytogenet Cell Genet 51:452–458
Tanner JM, Whitehouse RH (1976) Clinical longitudinal standards for height, weight, height, velocity, weight velocity, and stages of puberty. Arch Dis Child 51:170–179
Tedeschi B, Porfirio B, Vernole P, Caporossi D, Dallapiccola B, Nicoletti B (1987) Common fragile sites: their prevalence in subjects with constitutional and acquired chromosome instability. Am J Med Genet 27:471–482
Tedeschi B, Vernole P, Sanna ML, Nicoletti B (1992) Population cytogenetics of Aphidicolin-induced fragile sites. Hum Genet 89:543–547
Trush MA (1984) Activation of bleomycin A2 to a DNA-damaging intermediate by phorbol ester-stimulated human polymorphonuclear leukocytes. Toxicol Lett 20:297–302
Trush MA, Kensler TW (1991) An overview of the relationship between oxidative stress and chemical cancerogenesis. Free Radic Biol Med 10:201–209
Underwood LE (1984) Report of the conference on uses and possible abuses of byosinthetic human growth hormone. N Engl J Med 311:606–608
Underwood LE (1989) The risks of growth hormone therapy: does growth hormone influence tumor formation and tumor growth; In: Frisch H, Thorner MO (eds) Hormonal regulation of growth. Serono Symposia Publications, Raven Press, New York, pp 231–239
Vernole P, Tedeschi B, Caporossi D, Nicoletti B (1988) Common fragile sites and human cancer. A study on lymphocytes from neuroblastoma patients. Cancer Genet Cytogenet 36:13–23
Walker JM, Bond SA, Voss LD, Betts PR, Wootton SA, Jackson AA (1990) Treatment of short normal children with growth hormone a cautionary tale? Lancet 336:1331–1334
Weitberg AB, Weitzman SA, Destrempes M, Latt Sa, Stossel TP (1983) Stimulated human phagocytes produce cytogenetic changes in cultured mammalian cells. N Engl J Med 308:26–29
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tedeschi, B., Spadoni, G.L., Sanna, M.L. et al. Increased chromosome fragility in lymphocytes of short normal children treated with recombinant human growth hormone. Hum Genet 91, 459–463 (1993). https://doi.org/10.1007/BF00217772
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00217772